Veradermics Raises $75 Million in Series B Financing and Initiates Phase 2/3 Trial for Hair Loss• Investment to fund pivotal trials of VDPHL01, an oral investigational medicine for androgenetic alopecia (AGA), known as pattern hair loss (PHL) in men and women

Veradermics在B系列融资中筹集了7500万美元，并启动了脱发2/3期试验•投资资助VDPHL01的关键试验，VDPHL01是一种治疗雄激素性脱发（AGA）的口服研究药物，被称为男性和女性的模式脱发（PHL）

• Androgenetic alopecia/pattern hair loss is a large and unsatisfied market, affecting an estimated 80 million men and women in the U.S.

•雄激素性脱发/脱发是一个巨大且不令人满意的市场，估计美国有8000万男性和女性受到影响。

• Company names Amanda Birdsey-Benson from Suvretta Capital Management and Patrick Enright from Longitude Capital to Board of DirectorsNEW HAVEN, Conn., December 11, 2024-- Veradermics, a late clinical-stage aesthetics and dermatology-focused biopharmaceutical company developing first-in-class therapeutics for common dermatologic conditions, announced today the closing of a $75 million Series B financing.

•公司名称：Suvretta Capital Management公司的Amanda Birdsey Benson和Longitude Capital公司的Patrick Enright，以及康涅狄格州纽黑文市董事会的Patrick Enright，2024年12月11日——Veradermics，一家专注于临床晚期美学和皮肤病学的生物制药公司，今天宣布关闭7500万美元的B系列融资。

The financing was led by Suvretta Capital Management and included new investors Longitude Capital, Surveyor Capital (a Citadel company), Osage University Partners, and PhiFund. Existing investors, JW Childs Associates, Connecticut Innovations, and Vlad Coric, MD, also participated in this round. In connection with this financing, Amanda Birdsey-Benson, PhD from Suvretta Capital Management and Patrick Enright from Longitude Capital will join the Veradermics Board of Directors..

融资由Suvretta Capital Management牵头，包括新投资者经度资本（Longitus Capital）、Surveyor Capital（Citadel公司）、Osage University Partners和PhiFund。现有投资者JW Childs Associates、康涅狄格州创新公司和医学博士Vlad Coric也参加了这一轮。关于此次融资，Suvretta Capital Management的Amanda Birdsey Benson博士和Longitude Capital的Patrick Enright将加入Veradermics董事会。。

Proceeds from the financing will be used to fund the ongoing pivotal clinical development of Veradermics’ lead candidate VDPHL01 for the treatment of androgenetic alopecia (AGA), or pattern hair loss (PHL), the most common cause of hair loss affecting an estimated 80 million Americans.

融资收益将用于资助Veradermics的主要候选药物VDPHL01正在进行的关键临床开发，用于治疗雄激素性脱发（AGA）或模式性脱发（PHL），这是脱发的最常见原因，估计会影响8000万美国人。

Reid Waldman, MD, Veradermics’ Chief Executive Officer, commented, 'The initiation of our pivotal Phase 2/3 clinical trial in hair loss and completion of this $75 million financing marks a significant milestone for Veradermics. We are now well funded to advance our oral and potential best-in-class treatment for hair loss.

Veradermics首席执行官、医学博士里德·沃尔德曼（Reid Waldman）评论道：“我们在脱发方面的关键2/3期临床试验的启动以及这7500万美元融资的完成，标志着Veradermics的一个重要里程碑。我们现在有充足的资金来推进我们的口腔和潜在的最佳脱发治疗。

For too long, patients have struggled with hair loss or thinning hair with inadequate results. Our team is dedicated to solving this problem with an effective and simple to use oral medication. We are grateful to our new investors and extend an especially warm welcome to Amanda and Patrick as the newest members of our Board.

长期以来，患者一直在努力摆脱脱发或头发稀疏的困扰，但效果不佳。我们的团队致力于通过有效且简单的口服药物来解决这个问题。我们感谢我们的新投资者，并特别热烈欢迎Amanda和Patrick成为我们董事会的最新成员。

They both join a distinguished group of experienced life science operators and investors who share our mission to optimize better solutions for dermatologic conditions.”.

。

The first patient has been dosed in the pivotal Phase 2/3 trial evaluating VDPHL01 in AGA/PHL. The trial will enroll approximately 480 patients across 44 sites in the United States. The company plans to report topline data from the Phase 2 studies of VDPHL01 in the first half of 2025.

第一名患者已在评估AGA/PHL中VDPHL01的关键2/3期试验中服用。。该公司计划在2025年上半年报告VDPHL01第二阶段研究的基线数据。

Amanda Birdsey-Benson, PhD, Managing Director at Suvretta Capital Management, added, 'As investors, we are excited to support Veradermics as it enters late-stage, pivotal studies of a differentiated therapy within a large aesthetic market. Despite the widespread prevalence and emotional toll of hair loss, this common dermatologic condition has seen little innovation and lacks quality treatment options.

。尽管脱发的普遍流行和情绪受损，但这种常见的皮肤病几乎没有创新，缺乏优质的治疗选择。

There is a significant unmet need and strong market demand for an FDA-approved oral treatment for pattern hair loss. If approved, VDPHL01 could provide a much-needed, effective, and safe oral treatment to address this large, underserved market.'.

FDA批准的脱发口服治疗有很大的未满足需求和强大的市场需求。如果获得批准，VDPHL01可以提供急需的，有效的和安全的口服治疗，以解决这个庞大的，服务不足的市场。”。

About Veradermics

关于Veradermics

Veradermics is a late clinical-stage aesthetics and dermatology-focused biopharmaceutical company developing first-in-class treatments for common dermatologic conditions. The company’s lead candidate, VDPHL01, is a non-hormonal oral therapeutic that is currently being evaluated for the treatment of AGA/PHL in both men and women.

Veradermics是一家专注于晚期临床美学和皮肤病学的生物制药公司，为常见皮肤病开发一流的治疗方法。该公司的主要候选人VDPHL01是一种非激素口服治疗药物，目前正在评估其对男性和女性AGA/PHL的治疗效果。

Additional pipeline programs address common dermatologic conditions including common warts and molluscum contagiosum. For more information, please visit www.veradermics.com and follow us on LinkedIn.Contact: .

其他管道计划解决常见的皮肤病，包括常见的疣和传染性软体动物。有关更多信息，请访问www.veradermics.com并在LinkedIn上关注我们。联系人：。。

Company Contact:

公司联系人：

info@veradermics.com

info@veradermics.com

Media Contact:

媒体联系人：

Mike Beyer, Sam Brown Healthcare Communications

Mike Beyer，Sam Brown Healthcare Communications

Mikebeyer@sambrown.com

Mikebeyer@sambrown.com

312-961-2502

312-961-2502